Reason(s) for refusal should be documented. iv) Participants must have not received more than 3 prior systemic therapies. v) Concurrent chemotherapy administered with primary radiation and adjuvant chemotherapy given following completion of radiation therapy do not count as systemic therapies, though participants who progressed less than 6 months from primary platinum-based therapy are eligible. vi) Participants must have been offered a nd/or have received or refused at least 1 prior approved immune therapy regimen, that is considered standard of care for their disease stage and condition, in the country where they are receiving treatment, if such a regimen exists. Reason(s) for refusal should be documented. g) MEL i) Participants must have histologically confirmed recurrent or metastati c melanoma not amenable to local therapy with curative intent (surgery with or without chemotherapy) ii) Participants must have known BRAF and NRAS mutation status. iii) Participants must have r eceived and progressed/been intolerant of at least 1 but no more than 3 prior systemic therapies for metastatic and/or unresectable disease and have been considered for all other potentially efficacious therapies. iv) Participants must have been offered a nd/or have received or refused at least 1 prior approved immune therapy regimen, that is considered standard of care for their disease stage and condition, in the country where they are receiving tr eatment, if such a regimen exists. Reason(s) for refusal should be documented. h) RCC i) Participants must have histologically confirmed advanced or metastatic RCC with a clear cell component, not amenable to curative surgery. ii) Must have received at least 1 but not more than 3 prior systemic therapies in the advanced or metastatic setting. Systemic therapies may include anti-angiogenic therapy regimens (including but not limited to sunitinib, sorafenib, pazopanib, axitinib, tivozanib, and bevacizumab), cytokine therapy (eg, IL-2, IFN- α), vaccine therapy, or treatment with cytotoxics. Revised Protocol No.: 04 Date: 31-May-2019 75 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS iii) Participants must have evidence of p rogression on or after the last treatment regimen received and within 6 months prior to study enrollment. iv) Participants must have been offered a nd/or have received or refused at least 1 prior approved immune therapy regimen, that is considered standard of care for their disease stage and condition, in the country where they are receiving tr eatment, if such a regimen exists.